Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

Barring a last-minute reversal, 2018 will likely end as a down year for the biotech industry, at least in terms of stock performance.